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Abstract 
Plasma membranes of cultured HeLa S ceils bound the tritiated antitumor sulfonylurea [ 3 H]LYI81984 with high affinity (Ka of about 
25 nM). The number of binding sites, estimated to represent 30 to 35 pmol/mg protein, would represent a low abundance protein of the 
total plasma membrane proteins. The binding proteins appeared to contain one or more thiols in the binding site as high affinity binding 
of [3H]LY181984 was reduced by treatment with the covalent hiol blocking reagent, N-ethylmaleimide (NEM), or by oxidation with 
dilute hydrogen peroxide but was protected by glutathione or dithiothreitol. Elimination of binding of [3H]LY181984 by NEM was 
prevented by excess unlabeled LY181984 (an active sulfonylurea) but less so by excess LY181985 (an inactive sulfonylurea). The 
binding proteins were specifically labeled with thiol reagents following reaction of unprotected thiols with unlabeled thiol reagents. 
Binding proteins at ca. 34 kDa were labeled. Plasma membrane proteins after solubilization with SDS under strongly reducing conditions 
still bound sulfonylurea. [3H]LY 181984 binding to plasma membrane proteins resolved on SDS-PAGE correlated as well with proteins in 
the 30-40 kDa range. 
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1. Introduction 
In a previous communication [I], the existence and 
subcellular location of binding sites for the antitumor 
sulfonylureas were established using equilibrium dialysis 
and a radiolabeled antitumor sulfonylurea, [ 3 H]LY ! 81984, 
with plasma membrane vesicles of HeLa S cells. HeLa S 
cells were sulfonylurea-responsive, could be cultured read- 
ily and plasma membranes of good yield and fraction 
purity could be prepared. 
The sulfonylureas as antitumor agents were identified 
initially from a program of screening against in vivo 
murine solid tumors that had been implanted subcuta- 
neously [2-4]. Despite considerable clinical data, the site 
and mechanism of action of the antitumor sulfonylureas i
unknown [4,5]. The drugs have been reported to be mem- 
brane active and weak uncouplers of mitochondrial oxida- 
tive phosphorylation [6]. The latter activity, however, is 
given as well by sulfonylureas inactive as antitumor agents 
and may be unrelated to their antitumor action [7]. There is 
no evidence for cell cycle specificity of the drug, no 
inhibition of DNA, RNA or protein synthesis and no 
mechanistic parallels to other known antitumor agents 
[3-7]. Yet the chemotherapeutic opportunities afforded by 
the sulfonylureas might be expected to be expanded were 
basic information available on their molecular mode of 
action. In this report, sulfonylurea protection of inactiva- 
tion of sulfonylurea binding was used as an approach to 
identification of potential binding proteins of the HeLa 
plasma membrane. 
Abbreviations: biotin maleimide, N-biotinoyl-N'-(6-maleimidohe- 
xanoyl)hydrazide; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); DTT, 
dithiothreitol; HSA, human serum albumin; LY181984, N-(4-methyl- 
phenylsulfonyl)-N'-(4-chlorophenyl)urea; LY181985, N-(4-methylphen- 
ylsulfonyl)-N'-(phenyl)urea; NBT/BCIP, nitroblue tetrazolium/5- 
bromo-4-chloro-3-indoylphosphate; SDS-PAGE, sodium dodecylsulfate 
polyacrylamide g lelectrophoresis. 
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2. Materials and methods 
2.1. Equil ibrium binding 
Tritium-labeled N-(4-methylphenylsulfonyl)-N'-(4- 
chlorophenyl)urea ([3H]LYI81984) (Lot 497-1-291 spe- 
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cific activity 2898 mCi/mg) was obtained from Lilly 
Research Laboratories, Indianapolis, IN and diluted with 
dimethylsulfoxide. For binding studies, a multi-cell rotat- 
ing teflon cell equilibrium dialyzer (Spectrum Equilibrium 
Dialyzer, Spectrum Medical Instruments, Los Angeles, 
CA) with a dialyzing volume of 1 ml and a 47 mm 
diameter membrane (12 to 14 kDa molecular mass cut off) 
area was used. The dialysis membranes were prepared by 
soaking in water for 30 min followed by 30% ethanol for 
30 min and several changes of distilled water. Both sides 
of the chamber were supplied with 0.5 ml final volume of 
a buffer solution containing 25 mM Tris, 100 mM potas- 
sium chloride, 5 mM magnesium chloride and 1 /~M 
dithiothreitol, pH 7.4. To one side of each chamber was 
added the [3H]LY181984 in DMSO and the fraction to be 
evaluated. An equivalent amount of DMSO was added to 
the opposite side of the chamber and equilibrium estab- 
lished by rotating the cells at 25°C overnight. A 100 /zl 
sample was withdrawn from each chamber and radioactiv- 
ity was determined by liquid scintillation spectrometry. 
Radioactivity was determined at the 99% confidence level. 
Determinations were in triplicate to increase the confi- 
dence of specific binding to about _+ 5%. 
2.2. Growth of  HeLa cells 
HeLa S cells were grown as described [1] on minimal 
essential medium (S-MEM) (Jolik modified) with glu- 
tamine (244 mg/1) and phosphate (1.3 g / l  Na2HPO 4) 
plus 5% donor horse serum but without CaC12. Gen- 
tamycin sulfate (50 mg/1) and sodium bicarbonate (2 g/ l )  
were added. 
2.3. Preparation of  plasma membranes from HeLa cells 
The procedure described for preparation of plasma 
membranes from HeLa cells has been described previously 
[8,9] and is repeated here. Cells were collected by centrif- 
ugation for about 12 rain at 2000 rpm. The cell pellets 
were resuspended in 0.2 mM EDTA in 1 mM NaHCO 3 in 
an approximate ratio of 1 ml per 108 cells and incubated 
on ice for 10 to 30 min to swell the cells. Homogenization 
was with a Polytron homogenizer for 30 to 40 s at 10500 
rpm using a PT-PA 3012/23 or ST-probe and 7 to 8 ml 
aliquots. To estimate breakage, the cells were monitored 
by light microscopy before and after homogenization. At
least 90% cell breakage without breakage of nuclei was 
achieved routinely. 
The homogenates were centrifuged for 10 min at 1000 
rpm (175 X g) to remove unbroken cells and nuclei and 
the supernatant was centrifuged a second time at 1.4.106 
g min (e.g., 1 h at 23500 × g) to prepare a plasma 
membrane-enriched microsome fraction. The supernatant 
was discarded and the pellets were resuspended in 0.2 M 
potassium phosphate buffer in a ratio of approx. 1 ml per 
pellet from 5 • 108 cells. The resuspended membranes were 
then loaded onto an aqueous two-phase partitioning system 
constituted on a weight basis. 
The two-phase system contained 6.4% (w/w)  Dextran 
T-500 (Pharmacia), 6.4% (w/w) polyethylene glycol 3350 
(Fisher), and 5 mM potassium phosphate, pH 7.2. The 
plasma membrane-enriched microsome fraction (1 g) was 
added to the two-phase system and the weight was brought 
to 8 g with distilled water. The tubes were inverted 
vigorously for 40 times in the cold (4 ° C). The phases were 
separated by centrifugation at 750 rpm (150 × g) in a 
Sorvall HB 4 rotor for 5 min. The upper phases, enriched 
in plasma membranes, were carefully withdrawn with a 
pasteur pipette, diluted 5-fold with 1 mM sodium bicar- 
bonate and the membrane were collected by centrifugation 
(10000 × g in a HB rotor for 30 min). The purity of the 
plasma membranes was determined to be 90% by electron 
microscopy and analysis of marker enzymes. The yield 
was 20 mg plasma membrane protein from 10 l° cells. 
2.4. PAGE analysis 
Sodium dodecylsulfate polyacrylamide gel elec- 
trophoresis (SDS-PAGE) was according to Laemmli [10] 
using a Bio-Rad Miniprotean II gel system. For binding of 
[3H]LY181984, the minigels were loaded with 10 /xg of 
HeLa plasma membrane protein per lane and were soaked 
overnight in 50 mM Tris-Mes, pH 7, containing 10 mM 
dithiothreitol and 0.3 /zCi [ 3 H]LY 181984 in a total volume 
of 5 ml contained in a Ziplock 1 pint (5 in X 7 in) bag with 
shaking. The gels were rinsed with water and sliced with a 
razor blade into 2.5 mm segments. Radioactivity was 
determined for each individual segment. Values for a 
control gel, without plasma membrane, were subtracted. 
Two-dimensional gel electrophoresis was modified from 
O'Farrell [11]. In the first dimension, a 3.6% final acryl- 
amide mixture (28.38% acrylamide: 1.62% N,N'-methyl- 
enebisacrylamide) containing 9.5 M urea, 2% (3-((3- 
cholamidopropyl)dimethylammonio)- 1-propanesulfonate) 
(CHAPS), 2% ampholyte mixture (2 parts pH 3-10 to 1 
part pH 5-7), 10% ammonium persulfate and TEMED was 
poured into 3 mm × 13 mm (i.d.) pyrex tubes and over- 
layed with water saturated isobutanol. The gels were al- 
lowed to polymerize for 1-2 h. The polymerized gels were 
rinsed with deionized water and placed in a Hoefer Scien- 
tific GT series tube gel electrophoresis unit and overlayed 
with 20 #1 of urea extraction buffer containing 2.9 g 
ultra-pure urea, 2.0 ml 10% CHAPS, 0.25 ml ampholyte 
mixture, 0.1 ml 1 M dithiothreitol and 1.02 ml deionized 
water. The lower buffer chamber was filled with anolyte 
buffer consisting of 10 mM imino diacetic acid and the 
upper reservoir contained 10 mM ethylene diamine as the 
catholyte buffer. The gels were then prefocused at 200 V 
for 15 min, 300 V for 30 min and 400 V for 30 min. 
To solubilized membrane proteins, 150 /zl of a solution 
containing 9.5 M urea, 1% SDS and 1% /3-mercapto- 
ethanol were added followed by 50 /zl of a solution 
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containing 10% CHAPS and 10% ampholyte mix and 200 
/xl of a solution containing 2% CHAPS, 0.5% ampholyte 
mix and 9.5 M urea to a final volume of 400 /xl. The 
mixture was incubated for 1-2 h at room temperature and 
then centrifuged at 100000×g for 30 rain (SW 50.1 
rotor, Beckman). 
The solubilized sample was applied to the top of the gel 
and overlayed with 20 /xl of urea extraction buffer. The 
sample was focused at 400 mV for 16 h and at 800 mV for 
an additional 4 h. The last 20 min of focusing was at 1600 
mV. 
For the second dimension, the tube gels were extruded 
and embedded [11] on a horizontal 10% SDS-PAGE gel 
and separated as described above [10]. 
2.5. Binding q[ N-[ 14 C]ethylmaleimide 
To identify the proteins containing sulfonylurea pro- 
tected thiol groups indicated from binding studies, HeLa 
plasma membranes (100 #g membrane protein) resus- 
pended in 250 /xl of buffer containing 50 mM Tris-Mes, 
pH 7, were incubated with 1 /xM LY181984 (or 1 /xM 
LY181985) in DMSO or DMSO alone (0.1% final concen- 
tration) for 15 rain at 37°C followed by 500 /xM unla- 
beled N-ethylmaleimide for 15 min at 37°C to react with 
all unprotected thiol groups. Human serum albumin (1% in 
50 mM Tris-Mes, pH 7) was added to quench remaining 
unreacted N-ethylmaleimide and to facilitate release of 
sulfonylureas. The membranes were washed twice and 
then collected by microfuge centrifugation and resus- 
pended a second time in buffered albumin and collected by 
centrifugation. Finally, the washed membranes were re- 
acted with 5 /xCi N-[~4C]ethylmaleimide to label any thiol 
groups that may have been protected by the sulfonylurea. 
The reaction was quenched after 15 rain at 37°C with 0.5 
mM DTT and the membranes were collected by centrif- 
ugation. Plasma membrane proteins were displayed on 9 
cm 10% gels and analyzed by autoradiography with X- 
Omat S Kodak film. 
2.6. Biotin maleimide labeling 
Plasma membrane vesicles were treated for 15 min at 
37°C in 20 mM Tris-Mes, pH 7.0, containing 0.2 mM 
NaOH and 2 mM KCN with or without sulfonylurea s 
described above. The plasma membrane vesicles were then 
reacted at 37°C for 15 min with I mM unlabeled NEM, 
transferred to 4 ° C, diluted with cold buffer containing 1% 
human serum albumin and collected by centrifugation. 
After pelleting, biotin maleimide (2 mM) was added to 
label thiols exposed following the sulfonylurea treatment. 
After an additional incubation for 15 min at 37 ° C, mem- 
branes were pelleted at 4 °C, 0.5 mM dithiothreitol was 
added to quench unreacted biotin maleimide, washed and 
membrane proteins were displayed by SDS-PAGE on 10% 
gels. Biotinylated bands were identified after transfer to 
nitrocellulose by reaction with avidin-alkaline phosphatase 
(1 /xg/ml) with visualization with NBT/BCIP. 
3. Results 
High affinity binding of [3H]LY181984 was enhanced 
by reducing conditions during binding provided by 10 /xM 
dithiothreitol compared to the oxidized conditions pro- 
vided by 0.015% H20 2 (Fig. 1). The K d lor binding under 
reducing conditions was determined to be about 32 
nanomolar and n, the number of specific binding sites, 
was determined to be between 1 and 2 pmol/50 /xg 
protein (see also Table 1). With H20 2, the affinity of 
binding was reduced (K a = 0.1 /xM) but the number of 
sites appeared to be similar (Fig. 1). 
Treatment with the thiol reagent, N-ethylmaleimide 
(NEM), also influenced [3H]LY 181984 binding. However, 
with NEM the number of sites exhibiting high affinity 
binding was reduced (Table 1). Sites with an average Kj 
of ca 30 nM were equivalent to 1.4 pmol/50 /xg protein 
with untreated plasma membrane but were reduced to 0.3 
pmol/50 /xg protein following treatment with NEM. 
The reduction of high affinity binding by N-ethylmalei- 
mide was protected by first treating the membrane with 
LY181984 at a physiological concentration of 1 #M. 
Protection was evidenced by the observation that with 
sulfonylurea present during NEM treatment, there was 
only a 23% reduction in high affinity sites compared to 
76% reduction by NEM in the absence of sulfonylurea. At 
1 ~M, the tumor-inactive sulfonylurea LY181985 was less 
0.06 
0.05 
LU 
I,LI 
E:  0.04 II 
Z +DTT 
"-~ 0.03  Kd =o32 nM 
0.02  
f +H.O z & Kd = 0.1 ,uM • 
0.01 " " 
0.00 
0.0 0 .04  0 .08  0 .12  0 .16  0 .20  
BOUND. pMOLES/IO0 pL 
Fig. 1. Scatchard analysis of [3H]LYI81984 binding by purified plasma 
membranes of HeLa cells comparing reducing (10 /xM dithiothreitol) 
(r = 0.986) and oxidizing (0.015°A H:O 2) (r = 0.998) conditions. 
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Table 1 
High-affinity binding of [3H]LY181984 by HeLa plasma membranes 
reduced by treatment with N-ethylmaleimide (0.1 mM) and protected 
from reduction by N-ethylmaleimide by pretreatment with unlabeled 
LY181984 (1 /xM), an active anticancer sulfonylurea, but not by the 
inactive LY181985 (1 /.tM) 
Treatment a K d n 
(nM) (pmol/50/zg protein) 
None 38+ 16 1.44+0.22 
N-Ethylmaleimide 30+ 9 0.34+0.17 
LY181984+ N-ethylmaleimide 38 + 11 1.11 +0.19 
LY181985+ N-ethylmaleimide 28+ 6 0.64+0.14 
(80+22) b (1.17_+0.19) 
Binding was estimated by equilibrium dialysis at constant ligand (50 
pmol) and membrane protein (50 /~g) [1]. Values are averages of three 
(treatments) or six (none) determinations_+ S.D.. 
a All membranes received an amount of DMSO equivalent to a final 
concentration f 0.1%. 
b A population of binding sites with K d between 60 and 100 nM did 
appear to be protected by LY 181985 in the presence of N-ethylmaleimide 
(values in parentheses). 
DMSO LY181984 kD 
-205 
-116 
-97 
-66  
-45  
-29 
DMSO LY181984 kD 
~5 
a b 
Fig. 2. SDS-PAGE analysis of N-[14C]ethylmaleimide-labeling of HeLa 
plasma membrane peptide with sulfonylurea-protected thiols. HeLa plasma 
membranes were first reacted with unlabeled N-ethylmaleimide (NEM) in 
the presence of excess LY181984 (active), and the NEM and LY181984 
removed by washing with albumin. Protein bands protected by LY181984 
against reactions with NEM, and subsequently labeled with [t4C]NEM 
appeared consistently within the apparent molecular mass range 32 to 36 
kDa (arrow). Lane a, DMSO alone; lane b, DMSO plus 1 /xM LY181984. 
a b 
Fig. 3. SDS-PAGE analysis of biotin maleimide-labeling of HeLa mem- 
brane peptides with sulfonylurea-protected thiols. Conditions were as 
described in Fig. 2 except hat N-[L4C]ethylmaleimide wasreplaced by 
biotin-maleimide and visualization was by reaction with avidin-con- 
jugated alkaline phosphatase rather than autoradiography. Lane a, DMSO 
alone; lane b, DMSO plus 1 /xM LY181984. 
effective in protecting high affinity sites although a bind- 
ing component with a somewhat higher kDa was observed 
(values in parentheses) (Table 1). 
The response of [3H]LY 181984 to reducing and oxidiz- 
ing conditions (Fig. 1) and to N-ethylmaleimide treatment 
(Table 1) suggested an involvement of one or more sul- 
fonylurea-protected thiols in the binding site. This possibil- 
ity was investigated using both N-[Igc]ethyl - and biotin- 
maleimide. 
Using N-[14C]ethylmaleimide, the binding proteins pro- 
tected by sulfonylurea were labeled fol lowing reaction of 
unprotected thiols with unlabeled N-ethylmaleimide. When 
displayed on SDS-PAGE, minor protein components in the 
range of 32 to 36 kDa were consistently influenced by 
sulfonylurea presence (Fig. 2), 
Bands of the apparent doublet at 34 to 36 kDa were 
observed when LY181984 (active) was present during the 
initial treatment with unlabeled NEM (Fig. 2, lane b) but 
not with DMSO alone. Other radiolabeled components 
appeared not to be influenced by LY181984. 
Similar results were obtained using detection with bi- 
otin maleimide in place of N-[14C]ethylmaleimide with 
detection using avidin-labeled alkaline phosphatase (Fig. 
3). A band reactive with biotin maleimide at about 32 to 
34 kDa was observed in lane b where the membrane 
vesicles were initially treated with unlabeled NEM in the 
presence of LY I81984 (active). With LY181984 present 
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Fig. 4. As in Fig. 3 except comparing LY181985 (inactive) and DMSO 
with LY181984 (active). This experiment was repeated several times with 
consistent results. 
LY181984 
Table 2 
Binding of [ 3 H]LY 181984 by HeLa plasma membranes after denaturation 
in the presence of sodium dodecylsulfate. 
Fraction pmol bound 
Sample buffer (SDS) 0.3 
HeLa plasma membrane 4.0 
HeLa PM boiled in sample buffer 3.9 
Binding was estimated by equilibrium dialysis at constant ligand (50 
pmol) and membrane protein (100 /xg). 
during the treatment with unlabeled NEM, the protected 
component was at about 34 kDa (arrow). In these experi- 
ments, the inactive LY181985 was ineffective in thiol 
protection (Fig. 4). To confirm the presence of a radiola- 
beled band protected by active antitumor sulfonylurea, 
two-dimensionional gel analysis was employed (Fig. 5). 
The experiment was designed as described for Fig. 2 (lane 
b) and the major ['4C]NEM-labeled protein at 34 kDa was 
resolved as shown in Fig. 5. Compared were LY181985 
(inactive), DMSO and LY 181984 (active). The isoelectric 
point estimated from mobility in the first dimension was 
about 4.5. 
Further definition of the diarylsulfonylurea binding was 
facilitated by the unexpected observation that binding to 
plasma membranes solubilized in the presence of SDS and 
dithiothreitol was comparable to that of native membranes 
(Table 2). When resolved on SDS-PAGE gels, the major 
binding component localized to the molecular mass region 
between 30 and 38 kDa (Fig. 6). Additional binding was 
seen in the 50 to 60 kDa range and occasionally at about 
100 kDa and 150 kDa. These findings are of importance in
LY181985 
DMSO 
Fig. 5. Two-dimensional gel electrophoretic analysis of the 34 kDa region 
of HeLa plasma membranes protected from reaction with N-ethylmalei- 
mide (NEM) by incubation with sulfonylurea. The membranes were first 
reacted with unlabeled NEM in the presence of active (LY181984) and 
inactive (LYI 81985) or no (DMSO) sulfonylurea. The sulfonylurea was 
removed by centrifugation through sulfonylurea-free medium. Mem- 
branes then were subsequently reacted with [14C]NEM to label any 
sulfhydi~'l groups protected by the sulfonylurea. Both the active 
(LYl81984) and the inactive (LY181985) sulfonylureas protected al- 
though the degree of protection was considerably greater with the active 
LY181984. The isoelectric point of the major protected radioactive 
component was estimated to be about 4.5. 
6OO 
500 
400 
300 
200 
m 100 
m 0 
7- -1oo 
-200 
-300 
30-38 kD 
0 1 2 3 4 5 
CM 
Fig. 6. Binding of [3H]LY181984 to SDS-PAGE gel segments of HeLa 
plasma membranes compared to radioactivity in a blank gel. The gel 
regions in the 30 to 38 kDa range bound radioactivity significantly above 
that of a blank gel. Binding was determined in the presence of SDS-PAGE 
sample buffer which did not markedly affect sulfonylurea binding. Values 
are means of two gels analyzed in parallel _ mean average deviations as a 
function of distance migrated in centimeters (cm). The experiment was 
repeated several times with consistent results. 
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Fig. 7. Scatchard analysis (r = 0.968) of HeLa plasma membrane frac- 
tions from a preparative SDS-PAGE gel corresponding to a molecular 
mass of ca. 34 kDa. The fractions prepared under reducing conditions and 
corresponding to ca 100 Izg starting plasma membrane protein bound 
with high affinity (K a = 30 nM). 
that they provide direct confirmation of constituents bind- 
ing [3H]LY181984 in the same range of molecular masses 
as those binding NEM following LY 181984 protection. 
Binding to proteins of the molecular mass range 30 to 
38 kDa was confirmed by preparative SDS-PAGE where 
solubilization, electrophoresis and binding were carried out 
in the presence of dithiothreitol. Shown (Fig. 7) is a 
Scatchard analysis of binding of [3H]LY181984 to frac- 
tions 23 and 24 of the separation corresponding to a 
molecular mass of about 34 kDa did bind sulfonylurea 
with an apparent high affinity similar to that of the starting 
plasma membranes analyzed in parallel (K d = 30 nM). In 
addition, the purified protein fractions exhibited approxi- 
mately the same number of high affinity binding sites as 
the equivalent amount of starting plasma membrane loaded. 
Other fractions containing similar amounts of protein of 
relative molecular mass greater or less than 34 kDa did not 
bind [3H]LY181984 with high affinity. 
4. Discussion 
For the studies described, the diarylsulfonylureas were 
numbered experimental compounds, provided from the 
synthetic activities of Lilly Research Laboratories, Indi- 
anapolis, IN (Fig. 8). The compound esignated LY 181984 
was active against solid tumors. The structurally related 
compound designated LY181985 was inactive. Activity 
was defined on the basis of assays using murine solid 
tumors grown subcutaneously in an auxiliary site with 
treatment initiated the day following implantation [4]. 
A plasma membrane location for a site of action of the 
diarylsulfonylureas in HeLa cells was indicated from bind- 
ing studies with [3H]LY181984. Using equilibrium dialysis 
and [3H]LYI81984, the bulk of the specific binding of 
HeLa homogenates was localized to the plasma membrane 
[1]. Nuclei, mitochondria- or endoplasmic reticulum-en- 
riched fractions howed little or no specific binding. With 
freshly harvested cells, only minor binding was observed 
with the soluble fraction. 
Binding to plasma membranes was of high affinity with 
a Kj of about 30 nM. The number of binding sites, 
estimated to represent 30 to 35 pmol/mg protein, would 
correspond to a low abundance protein representing a
purification of about 1000-fold from the plasma membrane 
and about 6000-fold from the total homogenate assuming a
molecular mass of 34 kDa as indicated by the present 
findings. 
Preliminary indications of involvement of one or more 
thiols in sulfonylurea binding to the plasma membrane 
vesicles of HeLa cells came from findings where binding 
affinity, but not necessarily the number of sites, was 
dependent upon reducing conditions during binding. The 
covalently-binding thiol reagent N-ethylmaleimide also ad- 
versely affected high affinity binding but by reducing the 
number of high affinity sites. Similar results were obtained 
with the impermeant thiol reagent 5,5'-dithiobis(2-nitro- 
benzoic acid) (DTNB/EIIman's Reagent) (not shown). 
To attempt to label specifically a potential 
sulfonylurea-binding protein, HeLa S plasma membranes 
were incubated with LY181984 followed by a brief expo- 
sure to unlabeled N-ethylmaleimide to react with all un- 
protected thiol groups. The membranes were then cen- 
trifuged through buffer to release the bound sulfonylurea 
and ultimately reacted with either N-[t4-C]ethylmaleimide, 
biotin maleimide or coumarin maleimide with detection 
either by autoradiography, by blotting onto nitrocellulose 
and incubation with avidin-linked alkaline phosphatase or
with detection directly on the gels based on fluorescence 
(not shown). With all three methods, the active sulfonyl- 
urea LY181984 protected reactive functional groups, pre- 
sumably thiols, associated with a 36 kDa peptide and, to a 
lesser extent, with a 57 kDa peptide. Other proteins were 
labeled by the N-[~4C]ethylmaleimide pr sumably due to 
unmasking of cryptic thiols and/or other reactive groups 
by washing the membranes following the initial reaction 
with unlabeled N-ethylmaleimide. However, only en- 
hanced labeling of the 34 kDa component was observed to 
result from protection with active sulfonylurea during the 
initial incubation with unlabeled N-ethylmaleimide. The 
inactive sulfonylurea LY181985 was partially effective in 
0 ,~"~/Cf  
, , o ,  I II o 9 ,  
, .cAl~_J°  " ~, ~c~.J.~JJ ° ~ ,' 
LY-181984 /Y-181985 
Active Inactive 
Fig. 8. Structure ofdiarylsulfonylurea antitumor agents. 
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protection of binding sites in the experiments of Table 2 in 
that a normal number of sites, but having decreased affin- 
ity, were present compared to DMSO alone. However, in 
the labeling experiments of Figs. 2 to 5, the LY181985 
was ineffective in eliciting the markedly-enhanced labeling 
of a 34 kDa membrane component seen with LY181984. 
When resolved by two-dimensional electrophoresis, the 
sulfonylurea-protected component exhibited an acidic pl  
of about 4.5. 
An unexpected observation was the preservation of high 
affinity binding sites in HeLa plasma membranes after 
solubilization in detergent plus dithiothreitol. Binding was 
preserved as long as the mixture was maintained fully 
reduced. 
To further correlate the presence of a binding protein 
with material in the molecular weight range of 34 kDa, 
SDS-PAGE gels were incubated with [3H]LY181984 in 
the presence of dithiothreitol vernight. The gel was rinsed 
briefly to remove excess radioactivity and sliced. Analysis 
of gel slices compared to a blank gel loaded with sample 
buffer but without plasma membranes revealed specific 
binding principally in the 30 to 34 kDa portion of the gel. 
Binding in the molecular mass range 50 to 65 kDa and 
occasionally at higher molecular weights sometimes was 
observed as well but was more variable than that seen in 
the 32 to 36 kDa molecular mass range. 
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